Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04024800
Title Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)
Acronym NSABP FB-14
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Antigen Express, Inc
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Cancer Care Specialists of Central Illinois Decatur Illinois 62526 United States Details
Crossroads Cancer Center Effingham Illinois 62401 United States Details
Cancer Care Specialists of Central Illinois-Swansea Swansea Illinois 62226 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Stefanie Spielman Comprehensive Cancer Center Columbus Ohio 43212 United States Details
West Virginia University Morgantown West Virginia 26506 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field